Sana Biotechnology Inc logo


Sana Biotechnology Inc


Earnings Summary

Net Profits


Net Profits:

Sana Biotechnology Inc’s net profit fell -487.87% since last year same period to $-72.47Mn in the Q2 2022. On a quarterly growth basis, Sana Biotechnology Inc has generated -130.43% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Sana Biotechnology Inc post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

Sana Biotechnology Inc’s earning per share (EPS) estimates for the current quarter stand at -0.51 - a -8.51% fall from last quarter’s estimates.

EPS Estimate Current Year:

Sana Biotechnology Inc’s earning per share (EPS) estimates for the current year stand at -0.51.

Key Ratios

Key ratios of the Sana Biotechnology Inc post its Q2 2022 earnings

Return on Assets (ROA)
Return on Equity (ROE)
Dividend Per Share (DPS)


Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Sana Biotechnology Inc’s return on assets (ROA) stands at -0.16.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Sana Biotechnology Inc’s return on equity (ROE) stands at -0.39.

Dividend Per Share (DPS):

Sana Biotechnology Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. Sana shares a vision of repairing and controlling genes, replacing missing or damaged cells, and making its therapies broadly available to patients. Sana is more than 250 people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, and South San Francisco.

Sana Biotechnology Inc
188 East Blaine Street, Seattle, WA, United States, 98102